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Comparative Biology of Test Species
by Edward J. Calabrese*
This paper assesses the capacity of animal models to predict human response to carcinogenic agents
with consideration for the heterogeneity of humans. It is widely accepted that human susceptibility to
toxic substances, including carcinogens, is highly variable. Conventional rodent models are usually highly
inbred and valued for their ability to display characteristic homogeneity. Current practice assumes that
the homogeneity of response to toxic agents, including carcinogens, in the rodent model will be repre-
sentative of humans. The issue then becomes, To which of the broad spectrum of human responses are
specific animal models likely to be related?
This paperexaminesthe extent ofhuman heterogeneity overabroadrangeofbiochemical characteristics
(e.g., aryl hydrocarbon hydroxylase activity, epoxide hydrase activity, 3-glucuronidase activity, debriso-
quine hydroxylation, DNA-adduct formation) with emphasis on those biochemical characteristics that
affect responses to carcinogens. Examples are presented to compare the heterogeneity of selected animal
models for these biochemical characteristics as they relate to the spectrum of human responses noted
above. The paper presents atheoretical perspective for determining to which part ofthe human population
response spectrum common animal models are most likely to be extrapolated.
Introduction
There are a number of biological factors that may
enhance an individual's susceptibility for adverse health
effects from exposure to toxic substances, including car-
cinogens. These factorsinclude age, sex, genetic compo-
sition, nutritional status, and preexisting disease con-
ditions (1-5). The magnitude to which predisposing fac-
tors enhance susceptibility to toxic substances is known
only to a limited extent. The conventional wisdom em-
ployed in regulatory toxicology has been to assume that
most interindividual variations in response to noncar-
cinogenic toxic substances can be accounted for by a
factor of 10 (6). This position was supported in part by
Dourson and Stara (7), who reviewed the acute toxicity
response of rodents to a number of toxic agents. For
92% of the compounds studied, they found that a 10-
fold decrease in dose at the LD50 level would reduce
the exposure belowthe general range expected to result
in death. Inasmuch as these ranges were obtained with
inbred strains of laboratory rats, it is expected that
these rodents would have less variation in response to
toxic substances than the highly outbred and more het-
erogeneous human population.
The heterogeneity ofhuman response to toxic agents
would be expected to be much greater than that in the
widely used and highly inbred rodent model strains. An
important factor that needs to be documented is the
relationship between the limited capacity of highly
inbred strains ofrodents to predict accuratelythe range
of human response and the extent of interindividual
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variation among humans in response to toxic agents.
This information is necessary to establish the biological
basis of the uncertainty (safety) factor of 10 currently
recommended forwithinhuman species variation bythe
National Academy of Sciences (6) and used by the U.S.
Environmental Protection Agency (8) in establishing
acceptable exposure standards for noncarcinogens. Un-
fortunately, the recommended use of such an uncer-
tainty factor by the National Research Council (6) has
not been accompanied by supportive documentation.
The numerous problems related to the heterogeneity of
human responses to carcinogenic agents becomes ap-
parent with the understanding that current procedures
for quantitative risk assessment apply biomathematical
models to bioassay data. This procedure assumes that
the human distribution ofsensitivities will be described
by the response of inbred animal models. Current ap-
proaches for predicting human cancer risks from animal
studies do not consider human heterogeneity.
Variation in Response to Selected
Xenobiotics
The following examples will examine the range of
humanresponses with respecttothe degreeofvariation
in xenobiotic metabolism and other relevant end points
associated with susceptibility to carcinogenic agents.
The data presented will establish the range of human
variation in a number of parameters thought to affect
susceptibility to cancer-causing agents. A similar com-
parison of animal variation will be made and then com-
pared to the human response. This comparison permits
an assessment of relationships between the range ofE. J. CALABRESE
human responses to the responses of various animal
models. On the basis of this information the paper ad-
dresses the question, To what part of the spectrum of
human population variation do specific animal models
extrapolate?
Acetylation
Human. Certain aromatic amines are known to be
both animal and human carcinogens. These substances
tendto bemetabolized byacetylationtocompounds that
are less potent carcinogens. Both fast and slow acety-
lators havebeenidentifiedwithinthehumanpopulation.
In the United States, the distribution is roughly equal
(i.e., 50%/50%) among both Caucasians and blacks (2).
An assessment of the acetylation of about a dozen ar-
omatic amines by humans revealed a variation in re-
sponse of from 3.7- to 13.0-fold (9).
Animal. Lowerand Bryan (10)assessed therelative
capability ofN-acetyltransferase enzyme systems from
liver cytosols of various mammalian species (i.e., ham-
sters, guinea pigs, mice, and rats) to transfer acetyl
groups from acetyl-CoA to the amine function of the
carcinogens 2-aminofluorene (2-AF), 4-aminobiphenyl,
and 2-aminonaphthalene. The most readily acetylated
of these carcinogens in all four species was 2-AF, fol-
lowedby4-aminobiphenyland2-aminonaphthalene. The
highest enzyme activity was present in the liver cytosol
of the hamster, followed in order by the guinea pig,
mouse, and rat. Relative to the rat, which is arbitrarily
given 1 as a value, the mouse is 8, the guinea pig is 12,
and the hamster is 18. In contrast, doglivercytosol was
incapable of carrying out detectable N-acetylation of
any of the three carcinogenic arylamines studied.
Among the four commonly used animal models, the
capacity for the hamster to acetylate 2-AF is 9- to 10-
fold higher than a human fast acetylator and 120-fold
greater than a slow human acetylator. Guinea pigs and
mice were 5.7- and 4.6-fold more efficient acetylators
than the fast human acetylator for AAF. In marked
contrast, the rat displayed a capacity to acetylate 2-AF
in a manner that was intermediate to both the human
fast and slow acetylator phenotypes. More specifically,
the rat displayed about a 7-fold greater activity than
the human slowacetylatorand about 53% ofthe activity
ofthe fast acetylator.
In contrast to the species discussed, it is well known
that rabbits and humans display N-acetyltransferase
(NAT) activity for isoniazid (INH) and several other
arylamine drugs, including sulfanyridine, hydralazine,
andprocainamide. The activity ofthis enzymeis subject
to agenetic polymorphism that canbe expressed as fast
or slow acetylators. Genetic differences in the rate of
N-acetylation are associated with individual suscepti-
bility to toxicity from the chronic administration of
drugs like INH. In the case of INH, slow acetylator
humans areknowntobe atincreasedriskfordeveloping
peripheral neuropathies (11); fast acetylators have an
enhanced risk ofdeveloping hepatitis (12). Lower et al.
(13) hypothesized thatthe acetylatorphenotype isarisk
factor in the development ofarylamine-induced bladder
cancerinhumans. Evidence fromthesestudiesindicates
that the N-hydroxylated nonacetylated metabolite of
the arylamine is the bladder carcinogen. The risk for
bladder cancer may be a function of the individual's
capacityto acetylate and deacetylate arylamines follow-
ing N-hydroxylation.
The recognition that both rabbits and humans display
a genetic polymorphism with respect to acetylation has
led to speculation that the rabbit may be a predictive
animal model for population-based acetylation re-
sponses. Glowinski et al. (9) compared the rates oface-
tylation in both fast and slow acetylator phenotypes in
rabbits and humans for seven agents, including five ar-
ylamine carcinogens: a-naphthylamine, benzidine, p-na-
phthylamine, 2-AF, and methylenebis(O-chloroaniline)
(MOCA). In general, it was found that the fast acety-
lator rabbit displayed a rate of activity of from 10- to
50-fold greaterthanthe fast acetylatorhuman. The ace-
tylation for the slow acetylator rabbit ranged from 1/90
to 1/580 ofthe fast rabbit acetylator. However, the rab-
bits' acetylation activity levels were generally in the
range displayed by both the fast and slow human ace-
tylator, depending on the substrate. For example, the
slow acetylator rabbit was very similar to the slow hu-
man acetylator for 2-AF (0.013 vs. 0.021 ,umole/mg/hr)
and benzidine (0.016 vs. 0.019 ,umole/mg/hr), but more
closely comparable to the human fast acetylator for -
naphthylamine (0.28 vs. 0.23 ,umole/mg/hr).
The net result of such a comparison is that the rat
[Sprague-Dawley (SD) female] and the slow acetylator
New Zealand rabbit (both sexes) displayed N-acetyla-
tion activity for several substrates thought to be car-
cinogens in the range ofboth human fast and slow ace-
tylators, depending on the substrate. In general, the
hamster, guinea pig, and mouse displayed acetylation
activity that was markedly greater than that displayed
by the human fast acetylator. The one exception to this
is seen for the arylamine a-naphthylamine, where the
extent to which these three species exceeded the fast
human acetylator phenotype was not greater than 2.5-
fold.
Deacetylation
Animal. The capacity to deacetylate carcinogenic
arylacetamides has been shown by Lower and Bryan
(10) to be a significant risk factor affecting the occur-
rence of bladder cancer in the dog. This hypothesis is
derived from observations indicating that the N-hy-
droxy-nonacetylated metabolite is the carcinogenic
agent. The dog displays an increased risk of bladder
cancer because this species has the ability to N-hy-
droxylatethearomaticaminesbuthas alimitedcapacity
to acetylate such compounds; Similarly, with exposure
tocarcinogenicarylacetamides, thedoghasanenhanced
risk of bladder cancer from the capacity to N-hydrox-
ylate the agent and then to deacetylate it to the carcin-
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ogen. It is important to recognize that while nonace-
tylated arylamines that have been N-hydroxylated are
likely candidates for bladder carcinogens, the N-hy-
droxylated acetylated arylamines are likely candidates
for liver carcinogens. These examples show that en-
zymes carrying out the N-acetylation ofarylamines and
deacetylation of arylacetamides play an important role
as determinants of susceptibility to liver and bladder
cancer.
The relative capacity ofthe animal modelto acetylate
and deacetylate is then an important variable with re-
spect to arylamine-induced cancer. In the rat and
mouse, the ratio ofN-acetyltransferase to deacetylase
activity is very high relative to the dog. This may pro-
vide rodents with some protection against bladder can-
cer, but not for hepatocarcinogenesis (10,14).
Human. Littleisknownabouttherangeofvariation
with respect to deacetylation in humans. However, in
vivo studies with acetanilide indicate that humans and
rabbits, in contrast to dogs, are poor deacetylators of
acetylated aromatic amines (15).
Given the greater ability ofhumans to acetylate than
the dog and the lower human capacity to deacetylate
aromatic amines, it is likely that humans, especially the
fast acetylator phenotypes, would be at considerably
lower risk of developing an arylamine bladder cancer
than dogs.
Debrisoquine Oxidation
Human. Among humans, interindividual variations
exist with respect to the oxidation ofcarbon centers in
several drugs, including debrisoquine, guanoxan, and
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phenacetin. With respect to debrisoquine, Idle and
Smith (16) have reported that this guanidine-based an-
tihypertensive drug is metabolized by humans princi-
pally via alicylic oxidation to yield 4-hydroxydebriso-
quine (Fig. 1). The metabolic process is under the con-
trol of a single autosomal gene (17,18). Mbanefo et al.
(19) suggest that at least two alleles occur in the pop-
ulation that can affect the extent of this reaction. The
two alleles have been designated DH (extensive hy-
droxylation of debrisoquine) and DL (low hydroxyla-
tion). Homozygote individuals for the DL allele show a
significantly reduced capacity to 4-hydroxylate debri-
soquine and excrete the substance, for the most part,
unchanged. Individuals homozygous for the DL allele
make up the poor-metabolizing (PM) phenotype (19).
Individuals who are designated as genotypically homo-
zygous or heterozygous for D" are known to readily
hydroxylate debrisoquine. These are both extensive-
metabolizing (EM) phenotypes. The quotient, percent
dose eliminated as unchanged debrisoquine/percent
dose excreted as 4-hydroxydebrisoquine in the urine
after a single 10-mg oral dose, is bimodally distributed
and referred to as the "metabolic ratio." The EM phe-
notype exhibits metabolic ratios in the range of0.01 to
10.0; the PM phenotype displays metabolic ratios in the
rangeof18to200(Fig. 2). Ifoneconsideredtheextreme
range ofvalues given for the metabolic ratios of0.01 to
200, a difference of 20,000-fold metabolic variation is
seen in humans. However, it should be pointed out that
the majority (75-85%) of persons tested fall within a
10-fold range (16).
Animal. With respect to animal models, Al-Dab-
bagh et al. (20) assessed the extent ofanimal modeling
ofhuman polymorphic drugoxidationusingthemetabo-
lism of debrisoquine and phenacetin in rat strains.
Markedinterstraindifferenceswithrespecttothemeta-
bolic ratio were determined. The DA-strain rat dis-
played ametabolicratiofordebrisoquine of4.7, whereas
the Lewis rat had a metabolic ratio of 0.29 (Fig. 3).
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FIGURE 1. Metabolic disposition of debrisoquine in man. Modified
from Idle and Smith (16).
FIGURE 2. The genetic model in which three genotypically distinct
allele pairs give rise to two distinct phenotypes (16).
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FIGURE 3. Frequency distribution histogram ofmetabolic ratios (%
debrisoquine/% 4-hydroxydebrisoquine) for seven rat strains (20).
These values tended to simulate the activity for human
PM and EM, respectively.
Aryl Hydrocarbon Hydroxylase (AHH)
Variation
Human. Kouri et al. (21) reported about a 40-fold
interindividual variation ofbenzo[a]anthracene-induced
AHH activity in mitogen-activated human lymphocytes
(n = 300 people). In addition, Harris et al. (22) reported
that interindividual differences in AHH activities also
occur in other tissues, including the placenta (several
hundredfold) and the skin, kidney, and bronchus (less
than20-fold). Withrespect tohepatic variation ofAHH,
Pelkonen et al. (23) reported avariation of16-fold based
onsamples frompatients withvarioustypes ofdisorders
(e.g., cholelithiasis, icterus, cancer, liver injury).
Animal. Pelkonen et al. (23) assessed the level of
AHH activity in livers from adult humans, different
strains ofrats (noninbred SD, inbred SD, DA, Fischer,
and Wistar), guinea pigs, and rabbits. Based on mean
values, the activity of AHH in human liver was about
30 to 60% that of the male rat liver, depending on the
strain ofrat. No sex differences occur for humans, but
the female rat displays about 20 to 40% of the hepatic
activity of the male rat.
The range of human values was from approximately
20 to 320 pmole/g liver/min, with the mean being 100
units. This places the low human values in the range of
the female inbred rat, which has activity from about 15
to 20. The upper range of human activity is in the ac-
tivity zone of the male rat. Therefore, the upper and
lower tails of the human distribution curve appear to
be in the range of activity of the animal model.
Examination ofrabbit data revealed a generally sim-
ilar but somewhat lower (-60 units) activity than in
humans, along with no sex difference. It is interesting
to note that rabbits, like humans, are highly outbred
and that species outbreeding may have contributed to
the nearly 6-fold range in rabbit AHH activity (23).
With respect to the C3H mouse strain, the activity for
males and femalesis about3-fold thatofthemaleinbred
SD rat. This places the C3H mouse in the approximate
range of350 to 450 activity units, with a small standard
deviation (24).
Although it is instructive to note these comparisons,
itisimportant nottolose sightofthetotalbioactivation/
detoxification balance in various organs (e.g., liver) and
the relationship to active carcinogens.
Hepatic/Skin Epoxide Hydrase Activity
Human. In a survey of 163 individuals (most with
liverdisease), there was a63-fold range ofhepatic epox-
ide hydrase (EH) activity (with benzo[a]pyrene 1,1-ox-
ide as substrate). Approximately 80 to 90% of these
people were within a 10-fold range of activity. The he-
patic cytosol EH activity, determined with trans-stil-
bene oxide as substrate, varied over539-fold among 135
subjects (25). No data were presented for the deter-
mination ofwhat percentage ofthose studied fell within
a 10-fold range of activity.
Animal. HepaticmicrosomallevelsofEHinhumans
have been compared with those of several commonly
used animal models, including the mouse (NIH and
CEH strain), rat (Sprague-Dawley), guinea pig (Har-
tley), rabbit (NewZealand), andrhesusmonkey (24,26).
In general, the mouse, regardless ofstrain, displays the
lowest EH activitylevel. Ifthe CEHmouse strainvalue
is arbitrarily assigned a value of 1, then the values in
the other species including humans become: rat-5.8,
rabbit-6.2, guineapig-13.5, monkey-31.5, andhuman-
13.5.
The activity ofEH in the healthy skin ofone individ-
ual was measured for six substrates (27) and compared
with rat and mouse values. In addition, the skin from
six humans was assessed for its EH activity with re-
spect to one of the above substrates (e.g., benzo[a]py-
rene) to describe interindividual variation. In these in-
dividuals, variation in EH activity ranged from 175 to
447 ,umole of product/min/mg protein. There was no
obvious associationwithage, sex, ordrug/medicinalfac-
tors; however, skin location may be a confounding fac-
tor, as the samples were obtained from the abdomen,
thigh, and breast. In the interspecies comparison, the
human always displayed a higher activity than the
mouse, followedbythe rat. Thelowvalue of175activity
units was greater than the highest value of the rat or
mouse. These data suggest that for this parameter, the
human range of variation falls outside that of either
rodent model.
Unscheduled DNA Synthesis Repair-
Human Variation
Treatment of fibroblasts from presumably normal
people (n = 10) withthe carcinogensN-methyl-N-nitro-
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N-nitrosoguanidine (MNNG) and N-acetoxy-2-acetyl-
aminofluorene (NA-AAF) revealed a 2- to 6-fold inter-
individual variation in unscheduled DNA synthesis
(UDS) (28,29). Homozygous individuals for xeroderma
pigmentosum, a disease caused by impaired DNA re-
pair, display only 10% of the DNA repair capability of
normal persons when exposed to ultraviolet light, 4-
nitroquinoline (4NQO), and AAF (2). Differences in the
activities of both uracil DNA glycosylase and 06-alkyl-
guanine DNAtransalkylase (i.e., DNArepairactivities)
are 3- to 65-fold in various human tissues (22). These
findings, however, are based on a very modest sample
of 12 persons. Harris et al. (22) speculated that "one
can predict that studies measuring 06-alkylguanine
DNA transalkylase and other DNA repair enzymes in
larger human populations will reveal even wider vari-
ations."
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FIGURE 5. Interindividual variation in the binding levels ofbenzo[a]-
pyrene (BP) to DNA in cultured human colon. The values marked
with an asterisk are from colon explants prepared from immediate
autopsies (32).
Carcinogen Binding to DNA
Human. TRACHEA/BRONCHUS. Benzo[a]pyrene
(BP) bindingto DNAincultured humanbronchial tissue
was found to varyfrom 1- to 150-fold forn = 19 subjects
(Fig. 4). The range ofvariation was about 9-fold for80%
of the group studied (30).
COLON. BP binding to DNA in cultured human co-
lonic tissue has been found to vary over an approxi-
mately 30-fold range with n = 63. Approximately 90%
ofthe individuals were within a 15-foldrange (31). How-
ever, Autrup et al. (32) found a 100-fold variation in the
binding of BP to human colonic tissue among 32 indi-
viduals. Approximately 80% of those studied ranged
within a factor of 10 (Fig. 5).
ESOPHAGUS. BP binding to DNA in human esoph-
ageal tissue varied over a 20-fold range; however, only
six subjects were studied (22).
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FIGURE 4. The interindividual variation in the binding levels of
benzo[a]pyrene (BP) to DNA in cultured human bronchi. The val-
ues marked with anasterisk arefrompatientswithoutlung cancer,
and the remainder are from lung cancer patients (30).
Animal. TRACHEA/BRONCHUS. While only lim-
ited direct animalmodel comparisons with humans have
been conducted, Autrup et al. (33) found thatthe Syrian
golden hamster displayed about2.5 times as much bind-
ingofBP totrachealDNAas didthehuman. Thehuman
variation ranged from 3 to 17 units, or a nearly 6-fold
rangeofvariation. Littlevariationoccurredfortheham-
ster (26-27 units). Mouse (DBA strain) and rat (CD
strain) trachea activity averaged 9.25 with a narrow
range of variation of 9 to 11 units. In contrast to the
previous study, Daniel et al. (34) revealed similar bind-
ing capacity of BP to DNA in humans and hamsters
with the rat, dog, and monkey showing progressively
lower binding.
COLON. Autrup et al. (35) evaluated the capacity of
threecarcinogens [i.e., aflatoxin (AFB), benzo[a]pyrene
(BP), and dimethylhydrazine (DMH)] to bind to the
DNA of cultured rat (male CD strain, 4-5 weeks old)
and human colonic tissue (i.e., nontumorous). They
found that the mean level forbinding ofAFB and DMH
to colonic DNA was significantly higher (p < 0.01) in
the rat than in the human by 8.3-fold and 2-fold, re-
spectively. No statistically significant differences were
found for BP binding. Of great interest is the obser-
vation that the human colonic DNA displayed wide in-
terindividual variation in binding levels for all three
carcinogens [AFB (70-fold in 24 cases), BP (130-fold in
103 cases), and DNH (80-fold in 66 cases)]. In contrast,
the variation seen in the animal tests was markedly
smaller. For example, the standard deviations in the
rat data with respect to a percentage ofthe mean value
for AFB, BP, and DMH were 1.5, 8.2, and 2.3%, re-
spectively. For humans the comparable values were
126, 99, and 103%.
3-Glucuronidase Activity
Tissue. The level ofP-glucuronidase in multiple tis-
sues has been studied in a variety of animal species as
well as in humans. Table 1 provides a comparison ofthe
,3-glucuronidase activity ofvarious mammalian tissues.
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Table 1. Comparative 3-glucuronide activity of mammalian tissues.a
Intestinal contents Large Small
Species Small Large Liver Kidney Lung Spleen Brain intestine intestine Stomach
Mouse
High activity strains 2000-4000 1000-4500 - 4000-11,000 100
Mouse
Low activity strains 200-400 250-900 1300 20
Rat 100-300 3000 15,000-30,000 4000-6000 5000 15,000-30,000 150 3500 3000-5000
Human - 3000 2000 500 6500 Trace - 200-10,000
Rabbit 10-250 2000 5000 300 - 150 300 800 40
Guinea pig - 4500 600-1700 5500 300
Hamster 4500 1100
aMost common method for tissue bioassays. Measured as phenolphthalein liberated from phenolphthalein ,B-glucuronide in 1 hr at 38°C in
microgram/gram moist tissue. Modified from Dutton (36).
Rat liver and lung activity levels are 10-fold greater
than human levels. Also, there are both low and high
activity mouse strains with the low mouse strain dis-
playing about 1/10 the activity of humans (36).
The excretion and possible detoxification of carcino-
gens such as DMBA are enhanced by glucuronidation
and can be markedly decreased when the activity ofP-
glucuronidase is chemically inhibited by D-glucaro-1-4-
lactone. Factors such as this become a major consid-
eration when determining an individual's susceptibility
to these carcinogens. Treatment with the lactone re-
duced the level of P-glucuronidase in that tissue by ap-
proximately45% andreducedtheincidenceofmammary
tumors by 70% in rats (37). The authors speculated that
"inhibition ofB-glucuronidase activityincreasesthe pro-
portion ofDMBA which is sequestered and excreted as
the glucuronide and therefore is unavailable for acti-
vation to the proximal carcinogen."
It maybespeculated thathumansshouldbe at alower
risk than rats since they display about 10-fold less I8-
glucuronidase activity. The data available for assessing
the extent to which humans vary in tissue P-glucuroni-
dase activity are very limited. Nevertheless, several
studies have indicated that wide variation does exist
(38,39), and there is speculation that these variations
contribute to the occurrence of differential susceptibil-
ity of cancer in the population.
Gastrointestinal Tract. Gastrointestinal tract (GI)
levels of ,B-glucuronidase activity are also highly vari-
able in humans and may markedly affect the response
to some carcinogenic agents. P-Glucuronidase levels in
the small intestine are principally derived from gut mi-
croflora and are affected by diet. Since the diet varies,
it is likely that the gut microflora also vary in the type
and quantity ofmicroorganisms and the level of P-glu-
curonidase activity. Persons receiving antibiotic treat-
ment would have a depressed level of ,B-glucuronidase
activity, depending upon the action of the drug on gut
microflora (40).
Many carcinogenic agents such as BP and DMBA are
conjugated with glucuronic acid and excreted via the
bile. Itisimportanttonotethatcompounds maybecome
hydrolyzed by ,-glucuronidase while in the small intes-
tine and enter into enterohepatic circulation, thereby
increasing their residence time in the body. Individuals
with low ,3-glucuronidase activity in the small intestine
would be expected to have a reduced enterohepatic cir-
culation of agents conjugated with glucuronic acid and
secreted in the bile.
In terms of commonly employed animal models, it
should be pointed out that mice and rats, respectively,
areestimatedtohaveapproximately60,000-and 15,000-
fold greater P-glucuronidase activity in the proximal
small intestine than humans (41). Such findings suggest
that these models may display considerably greater en-
terohepatic circulation of carcinogens conjugated with
glucuronic acid and excreted via the bile. As seen in
Table 2, the rabbit and guinea pigmodels offer a closer
approximation to the human even though these species
far exceed estimated human values (41).
Biological Basis for Expanding
Current Extrapolation Procedures
The previous examples indicate that there is exten-
sive variation of the biochemical parameters believed
to be associated with important phases in the process
of carcinogenesis, including bioactivation and deacti-
vation, in the human population. The extent ofthis var-
iation differs with the specific parameter and is likely
to be related to the sample size and characteristics of
the population from which samples were derived. The
human population from which samples have been de-
rived is usually less than several hundred individuals
and at times may be less than 20. In addition, the sam-
ples employed may not be representative of a larger
population group. Investigators frequently have little
Table 2. Estimated 3-glucuronidase activity in the small
intestine of the human and four laboratory animal species.'
Estimated ,B-glucuronidase activity, ,ug/g tissue
Proximal small Distal small
Species intestine intestine
Human 0.02 0.9
Rabbit 2.4 45.4
Guinea pig 2.7 139.0
Rat 304.0 1341.0
Mouse 1200.0 5015.0
aModified from Draser and Hill (41).
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choicebuttoconductthesestudiesonthebasisofhuman
specimens received by happenstance. Consequently, al-
though the data indicate that human ability to bioacti-
vate certain mutagens/carcinogens varies, it is not pos-
sible to make confident generalizations about eitherthe
extent ofthis heterogeneity in the human population or
the distribution of the range of effect. Available data
indicate that human variation in response to carcino-
genic agents is generally much greater than that ob-
served in commonly studied laboratory species. Most
reports seldom state which segment ofthe human pop-
ulation the animal model is thought to represent, al-
though it is generally assumed that the model repre-
sents the population mean.
The examples described inthispaperexpandthe gen-
eral approach by illustrating how information about a
group ofhumans and various animal models can be ex-
trapolated. For example, with respect to acetylation,
the most appropriate model depends on the human
phenotype. While it is necessary to combine this infor-
mation with variations in the ability to N-hydroxylate
and deacetylate arylamines to provide an accurate es-
timate of arylamine-induced cancer risk, this type of
assessment affords a new population-based interpre-
tationalapproachtodeterminingthehumansignificance
ofbioassay data.
The recognition that heterogeneity ofresponse to the
expression of biochemical parameters associated with
the risk ofdeveloping chemically induced cancer in the
human population presents the opportunity to use in-
terspecies differences as an asset ratherthan aliability.
For example, it could be that one animal model may
reasonably simulate the response ofone segment ofthe
population (e.g., fast acetylator), while another model
may best simulate another segment of the population
(e.g., slow acetylator). Another approach may be for
the testing agency to select the animal model on the
basis ofwhich segment ofthe population that it desires
to simulate. Thus, it maybe possible to select an animal
model that more closely simulates a potential human
high-risk group. This type ofknowledge may be ofcon-
siderable value forinterpreting estimates ofcancerrisk
to humans when these are based on biomathematical
models.
The approach described in this paper may be of as-
sistance inthedevelopment ofprospective assessments,
in the development ofnew protocols for testing, and in
the reinterpretation of past studies to assess their ex-
trapolative value. For example, the results of cancer
bioassay studies in the dog have been used by the Oc-
cupational Safety and Health Administration (OSHA)
to quantitatively assess the bladder cancer risk from
exposure to the carcinogenic agent MOCA (42). Avail-
able information indicates that MOCA must be N-hy-
droxylated and not acetylated and that the dog lacks
the ability to acetylate aromatic amines. The fact that
the doghasamorefavorabledeacetylase/acetylaseratio
than humans for the metabolism of aromatic amines
would suggest that the dog is likely to overpredict hu-
man risk.
Summary
The relationship between human heterogeneity and
susceptibility to the effects of toxic agents, including
carcinogens, has become increasingly recognized. Iden-
tification of the causes of differential susceptibility is
presently an active area of biomedical/toxicological re-
search. The highly varied susceptibility of humans to
environmental agents can be related to the fact that
humans are ahighly outbred species that follow abroad
variety of dietary patterns and divergent lifestyles. In
contrast, the responses of humans to toxic agents are
currently predicted from highly inbred rodent strains
raised on standardized diets and housed under similar
environmental conditions. This paper describes an ap-
proach for addressing this principal issue ofanimal ex-
trapolation with a perspective for biologically plausible
interpretations of cancer bioassay data.
An earlier version ofthis paper was published by E. J. Calabrese.
Animal extrapolation and the challenge of human heterogeneity. J.
Pharmacol. Sci. 75 (11): 1041-1045 (1986).
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